Previous 10 | Next 10 |
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q3 2023
2023-11-06 12:12:03 ET More on X4 Pharmaceuticals X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market X4 submits New Drug Application to FDA for WHIM syndrome drug Seeking Alpha’s Quant Rating on X4 Pharmaceuticals For...
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2023 and provid...
2023-10-31 10:35:43 ET More on X4 Pharmaceuticals X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market X4 Pharmaceuticals, Inc. (XFOR) Q2 2023 Earnings Call Transcript X4 submits New Drug Application to FDA for WHIM syndrome drug ...
2023-10-31 10:04:17 ET DENVER, Colo., Oct. 31, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Cardio Diagnostics Holdings Inc (NASDAQ: CDIO), X4 Pharmaceuticals Inc (NASDAQ: XFOR), SciSparc Ltd (NASDAQ: ...
FDA sets a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024 If the NDA is approved, company eligible to receive a Priority Review Voucher (PRV) resulting from mavorixafor’s rare pediatric designation in WHIM syndrome NDA supported by positive resu...
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors. ...
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conferen...
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Morgan Stanley 21 st Annual G...
2023-09-05 12:07:16 ET More on X4 Pharmaceuticals Seeking Alpha’s Quant Rating on X4 Pharmaceuticals Historical earnings data for X4 Pharmaceuticals Financial information for X4 Pharmaceuticals X4: De-Risking By WHIM Indication, Promising Potential For...
News, Short Squeeze, Breakout and More Instantly...
X4 Pharmaceuticals Inc. Company Name:
XFOR Stock Symbol:
NYSE Market:
X4 Pharmaceuticals Inc. Website:
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of...
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming H.C. Wainwright 2 nd Annual BioConnect Investor Co...
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavo...